From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|July 20, 2022
Daily Medication Pearl: Hyqvia Immune Globulin Infusion 10%
Author(s)Saro Arakelians, PharmD
Hyqvia is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of primary immunodeficiency in adults.
Advertisement
Medication Pearl of the Day: Hyqvia Immune Globulin Infusion 10%
Indication: Hyqvia is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of primary immunodeficiency (PI) in adults.
Insight:
- Dosing: May start from 7.5 g up to 30 g infusions depending on the patient.
- Dosage forms: Comes in 10%, 2.5, 5-, 10-, 20-, and 30-gram proteins.
- Adverse events: The most common adverse reactions observed in clinical trials in >5% of subjects were local reactions, headache, antibody formation against recombinant human hyaluronidase (rHuPH20), fatigue, nausea, pyrexia, and vomiting.
- Mechanism of action: The immune globulin infusion 10% (human) provides the therapeutic effect of Hyqvia. The recombinant human hyaluronidase of Hyqvia increases dispersion and absorption of the immune globulin infusion 10% (human). The immune globulin infusion 10% (human) of Hyqvia supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents.
Source:
Advertisement
Related to this article
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.
Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
3
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5